bl-m05d1
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 19, 2024 (NCT06349811)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Claudin-18INHIBITOR
CLDN18 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07021066 | Phase 1 | Jul 30, 2025 | SystImmune Inc. |
| NCT06349811 | Phase 1 | Apr 19, 2024 | Baili Pharmaceutical Group, Peking University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| SystImmune Inc. | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1